Cellphire Therapeutics

Executive Summary

Cellphire Therapeutics is a private biotech company focused on preventing deaths from uncontrollable hemorrhage, a leading cause of preventable death in the U.S. for those under 45. The current standard of care, liquid-stored platelets (LSP), has a maximum shelf life of only 7 days, severely limiting inventory buffers and access in critical situations. Cellphire is developing Thrombosomes®, a lyophilized (freeze-dried) platelet product that can be stored at room temperature for extended periods, potentially revolutionizing trauma care and military medicine by providing immediate hemostatic capability without the logistical constraints of fresh platelets. The company's mission is to ensure that no one dies from controllable hemorrhage due to product unavailability.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 clinical trial interim data readout for Thrombosomes in trauma patients60% success
• Q1 2027FDA Type B meeting to discuss pivotal trial design and registration pathway80% success
• Q2 2027Strategic partnership or licensing deal for U.S. or ex-U.S. commercialization rights50% success